ALSPW Spineway SAS

Approval of the reverse stock split by the Extraordinary General Meeting

Approval of the reverse stock split by the Extraordinary General Meeting

Press release         Ecully, July 26, 2022 – 8.30 am



Launch of a Spineway share consolidation

The Extraordinary General Meeting of Spineway's shareholders was held on Monday, July 25, 2022 at 5:00 p.m. at the Company's headquarters. The resolutions presented, including those relating to the share consolidation, were approved by the shareholders with the exception of the 5th resolution, concerning the capital increase reserved for employees, which was rejected in accordance with the Board of Directors' recommendation. The Board of Directors of the Company, which met on the same day, decided to implement the share consolidation.

Watch the video of Stéphane Le Roux, CEO of Spineway

Implementation of the share consolidation

At its meeting of July 25, 2022, the Spineway Board of Directors decided to implement the reverse stock split of Spineway's share capital approved by the Extraordinary Shareholders' Meeting of July 25, 2022 under the terms of its first resolution, at the rate of one (1) new share to be issued for forty thousand (40 000) existing shares to be consolidated. Taking into account the exchange parity retained, as a result of the consolidation, the number of outstanding shares will be divided by forty thousand (40 000). The par value of the Spineway share will be increased in proportion to the consolidation ratio and will increase from a ten thousandth (0.0001) of euro to four (4) euros.

The purpose of this consolidation is to reduce the volatility of Spineway's share price, promote its stabilization and thus better reflect the Group's development prospects.

This consolidation has no impact on the amount of share capital, only the par value of the share and, concomitantly, the number of shares in circulation are modified.

The consolidation is therefore a purely technical adjustment, with no direct impact on the total value of the Spineway shares held by each shareholder. The mnemonic code (ALSPW) will remain unchanged. However, the ISIN code of the new SPINEWAY shares (post consolidation) will become FR001400BVK2.

Grouping methods

All the terms and conditions of the business combination were approved by the Board of Directors at its meeting of July 25, 2022 and are detailed in the notice of business combination which will be published in the Bulletin des Annonces Légales Obligatoires (BALO) on July 29, 2022.

The main terms are as follows:

  • Basis of consolidation: exchange of forty thousand (40 000) existing shares with a par value of a ten thousandth (0.0001) of euro for one (1) new share with a par value of four (4) euros.
  • Number of shares subject to the reverse split: all the shares comprising the capital of Spineway, i.e. twenty-three billion four hundred seventy-three million nine hundred twenty-one thousand and eight hundred seventy-four (23 473 921 874) shares.
  • The number of shares subject to and to result from the reverse split will be increased, as the case may be, by the shares issued following the exercise of the rights of the beneficiaries of any securities giving access to the Company's share capital, or by the shares that would be issued as from the date of this notice.
  • Number of post-consolidation shares: five hundred eighty-six thousand and eight hundred forty-eight (586,848) shares with a par value of four (4) euros each.
  • Start date of the business combination: August 16, 2022.
  • Effective date of the combination: September 14, 2022.
  • Each shareholder will be automatically allocated, by his financial intermediary, one (1) new share for forty thousand (40 000) old shares held. The shareholders holding a number of shares multiple of forty thousand (40 000) will thus have no steps to take.
  • Shareholders who do not hold a number of existing shares corresponding to a whole number of new shares must personally purchase or sell the fractional shares between August 16, 2022 and September 14, 2022 inclusive, in order to obtain a number of shares multiple of forty thousand (40 000).
  • After this period, the new shares which could not be allotted individually and corresponding to fractional rights will be sold on the stock exchange by the account holder within 30 days from September 14, 2022, in accordance with the provisions of articles L.228-6-1 and R.228-12 of the French Commercial Code and with market practice. The proceeds from the sale will be allocated in proportion to the fractional rights among the shareholders who would not have been able to obtain a number of shares in multiples of forty thousand (40 000) during the consolidation period.
  • At the end of the consolidation period, the old shares not presented for consolidation will be delisted and will lose their voting rights and their right to dividends.

Indicative schedule of consolidation operations

Share exchange period
August 16, 2022Start of exchange operations
September 14, 2022End of exchange operations
Consolidation operations
September 14, 2022Last listing of the old shares on Euronext Growth (ISIN code: FR0011398874)
September 15, 2022First listing of the new shares on Euronext Growth (ISIN code: FR001400BVK2)
September 19, 2022Allocation of the new shares
Breakage management
September 14, 2022Start of compensation of fractional shares by financial intermediaries
October 14, 2022Deadline for the compensation of fractional shares by financial intermediaries

Upcoming : September 8th 2022, Results of the 1st semester 2022

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.

Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).

ISIN: FR0011398874 - ALSPW        

Contacts:





SPINEWAY



Shareholder-services line



Available Tuesday through Thursday



+33 (0)806 706 060




Elgible PEA / PME





ALSPW





Eunext Growth





AELIUM



Fince & Communication



Investor relations



Solène Kennis



Attachment



EN
26/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

 PRESS RELEASE

Spineway : Revenue growth in the third quarter

Spineway : Revenue growth in the third quarter Ecully, October 14, 2025 – 6:30 p.m. SPINEWAYRevenue growth in the third quarter In thousands of euros20252024Change as a %Q3 revenue3,0452,575   +18%Q2 revenue2,7453,465-21% Q1 revenue2,8283,070-8%9M revenue8,6189,110      -5% Unaudited consolidated data The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, benefited, in line with its expectations, from a deferral of orders from major accounts to the third quarter of 2025 and generated revenue of €3.0 million over the period, up from €2.6 millio...

 PRESS RELEASE

SPINEWAY : Croissance du chiffre d’affaires au 3ème trimestre

SPINEWAY : Croissance du chiffre d’affaires au 3ème trimestre Ecully, le 14 octobre 2025 – 18h30 SPINEWAYCroissance du chiffre d’affaires au 3ème trimestre En milliers d’euros20252024Variationen %CA 3ème trimestre3 0452 575   + 18%CA 2ème trimestre2 7453 465- 21%CA 1er trimestre2 8283 070      - 8%CA 9 mois8 6189 110       - 5% Données consolidées non auditées Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a bénéficié, conformément à ses anticipations, d’un report des commandes de grands comptes sur le 3ème trimes...

 PRESS RELEASE

Spineway : H1 2025 results - Continued improvement in results and fina...

Spineway : H1 2025 results - Continued improvement in results and financial position Press release         Ecully, July 30, 2025 – 7 p.m.   SPINEWAY H1 2025 results  Continued improvement in results and financial positionFull-year 2025 growth target confirmed In thousands of eurosConsolidated financial statements – UnauditedH1 2025H1 2024Revenue5,5736,535Cost of sales(1,702)(2,059)Gross margin% of revenue3,87069%4,47668%Net operating expensesOf which general operating costs(5,068)(2,086)(5,246)(2,232)Of which personnel expenses(2,374)(2,685)Operating income/(loss)(1,197)(770)Fina...

 PRESS RELEASE

SPINEWAY : Résultats semestriels 2025 - Poursuite de l’amélioration de...

SPINEWAY : Résultats semestriels 2025 - Poursuite de l’amélioration des résultats et de la situation financière Communiqué de presse        Ecully, le 30 juillet 2025 –19h SPINEWAY Résultats semestriels 2025 Poursuite de l’amélioration des résultats et de la situation financièreObjectif de croissance confirmé pour l’année 2025 En milliers d'eurosComptes consolidés – Non auditésS1 2025S1 2024Chiffre d'affaires5 5736 535Coût des ventes- 1 702- 2 059Marge brute% du CA3 87069%4 47668%Coûts nets d’exploitationDont coûts de fonctionnement- 5 068- 2 086- 5 246- 2 232Dont charges de personnel-...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch